Relmada Therapeutics, Inc. (RLMD)
$3.36-4.27%Close
SELLCRISIS · day 18
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $352M
- Beta
- 0.45
- P/E (TTM)
- -3.65
- Short % float
- 14.85%
- Days to cover
- 13.0
- SI change
- -7.2%
- 1W
- +2.44%
- 1M
- -24.32%
- vs SPY 1W
- +2.58%
- vs SPY 1M
- -26.83%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on RLMD?
- LOPJLB’s latest quantitative signal on Relmada Therapeutics, Inc. (RLMD) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is RLMD in?
- Relmada Therapeutics, Inc. (RLMD) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Relmada Therapeutics, Inc. (RLMD) do?
- Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, wh…